Abstract
The single oral loading dose of propafenone appears to be highly effective for conversion of recent-onset atrial fibrillation (AF), with a relatively rapid effect within 2 to 3 h and freedom from serious adverse effects [1]. Administration of flecainide, dofetilide, propafenone, or ibutilide is recommended for pharmacological cardioversion of AF (Class I Level of Evidence: A). A single oral bolus dose of propafenone or flecainide (“pill-in-the-pocket”) can be administered to terminate persistent AF outside the hospital once treatment has proved safe in hospital for selected patients without sinus or atrioventricular (AV) node dysfunction, bundle-branch block, QT-interval prolongation, the Brugada syndrome, or structural heart disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
